Vivesto AB

VIVE

SE0000722365

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 01/07/2024 BST			5-day change	1st Jan Change
0.2855 ^SEK	+4.20%		+5.74%	-29.94%

05-23	Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-26	Transcript : Vivesto AB - Special Call

Oasmia Pharmaceutical AB Elects Andrea Buscaglia as Members of the Board of Directors

May 27, 2021 at 10:09 am

Oasmia Pharmaceutical AB (publ) elected Andrea Buscaglia as members of the Board of Directors at its Annual General Meeting held on May 27, 2021.

Latest news about Vivesto AB

Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Transcript : Vivesto AB - Special Call	03-26
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial	03-07	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Vivesto's International Patent Application for XR-18 Receives Positive Decision	01-30	CI
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet	12-28	MT
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment	12-28	CI
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil	12-19	CI
Vivesto AB Announces Composition of Nomination Committee	11-23	CI
Vivesto Abandons Apealea Partnership with Elevar Therapeutics	11-23	MT
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership	11-23	CI
Vivesto AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Pharmaceutical Group Vivesto to Delist from Frankfurt Bourse	18/09/23	MT
Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Vivesto Halts Patient Enrollment in Phase 1b Study for Prostate Cancer Treatment	04/08/23	MT
Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study	04/08/23	CI
Easing Eurozone Inflation Buoys EU Stocks to Higher Close on Friday	16/06/23	MT
Vivesto Jumps 12% on Successful US FDA Meeting for Veterinary Oncology Drug Candidate	16/06/23	MT
Vivesto AB Announces Positive Paccal Vet FDA Pre-Submission Meeting	16/06/23	CI
Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23	CI
Vivesto AB Initiates Clinical Development of Paccal Vet in Veterinary Oncology	20/03/23	CI
Vivesto AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23/02/23	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Vivesto Sublicensee To Cancel Swiss Regulatory Application For Cancer Drug	11/01/23	MT
Vivesto AB(OM:VIVE) added to OMX Nordic Small Cap Index	03/01/23	CI

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIVESTO AB	-29.94%	14.44M
ELI LILLY AND COMPANY	+56.86%	823B
NOVO NORDISK A/S	+43.90%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	324B
ABBVIE INC.	+9.94%	301B
ASTRAZENECA PLC	+16.08%	241B
ROCHE HOLDING AG	+2.29%	223B
NOVARTIS AG	+13.96%	218B
AMGEN INC.	+7.98%	167B

Other Pharmaceuticals

Vivesto AB

Equities

VIVE

SE0000722365

Pharmaceuticals

Oasmia Pharmaceutical AB Elects Andrea Buscaglia as Members of the Board of Directors

Latest news about Vivesto AB

Chart Vivesto AB

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals